Supriya Lifescience Ltd
NSE:SUPRIYA
Supriya Lifescience Ltd
NSE:SUPRIYA
Price:
367.05 INR
5.34%
Market Closed
Updated:
Jun 1, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
16.5
Current
11.8
Median
13.3
Industry
Higher
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=16.5
Enterprise Value
/
28.4B
EBITDA
1.7B
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| IN |
|
Supriya Lifescience Ltd
NSE:SUPRIYA
|
29.5B INR | 16.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 459 134.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.7B USD | 62.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 34.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
353B USD | 11.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
318B USD | 34.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
189B GBP | 174.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
184.2B CHF | 9.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.3B CHF | 8.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
162.4B USD | 12.7 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
16.5
2-Years Forward
EV/EBITDA
12.5
3-Years Forward
EV/EBITDA
10
You don't have any saved screeners yet
